newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports First Quarter 2026 Financial Results

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent ADC, advances into the